URB2
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| URB2 ribosome biogenesis 2 homolog (S. cerevisiae) | Ensembl:ENSG00000135763 | HGNC:HGNC:28967 | PA164727496 | 1q42.13 |
GO terms in URB2
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| CC | IBA | GO:0005730 | nucleolus |
| CC | IDA | GO:0005730 | nucleolus |
| CC | IDA | GO:0016235 | aggresome |
| CC | IDA | GO:0030496 | midbody |
| BP | IBA | GO:0042254 | ribosome biogenesis |
Gene expression in normal tissue: URB2
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in URB2
| Database | Pathway ID | Pathway Des. |
|---|
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD201 | SKI II | 3 |
| iGMDRD57 | Chloropentafluorobenzene | 1 |
| iGMDRD679 | Bistramide A | 1 |
| iGMDRD123 | Isoevodiamine | 3 |
| iGMDRD177 | Teniposide | 3 |
| iGMDRD375 | GW-405833 | 3 |
| iGMDRD307 | Manumycin A | 3 |
| iGMDRD772 | BRD4770 | 6 |
| iGMDRD1008 | SR-II-138A | 1 |
| iGMDRD299 | ICL 670 | 1 |
| iGMDRD670 | ML 210 | 3 |
| iGMDRD424 | Tamatinib | 9 |
| iGMDRD546 | BMS-754807 | 6 |
| iGMDRD286 | Nsc 632839 | 3 |
| iGMDRD367 | Ro 28-1675 | 2 |
| iGMDRD399 | Selumetinib | 3 |
| iGMDRD74 | Idarubicin | 3 |
| iGMDRD888 | Compound 44 | 3 |
| iGMDRD506 | Fedratinib | 4 |
| iGMDRD329 | Merck60 | 3 |
| iGMDRD562 | Navitoclax | 1 |
| iGMDRD300 | Tozasertib | 6 |
| iGMDRD268 | Cerulenin | 2 |
| iGMDRD524 | ISX-9 | 3 |
| iGMDRD137 | Indisulam | 2 |
| iGMDRD202 | Curcumin | 3 |
| iGMDRD434 | BMS-536924 | 7 |
| iGMDRD213 | SMR000068650 | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in URB2
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.